Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants

A Phase 1, Open-label, Single-site, Randomized, Single-dose, Three-way, Crossover Study to Assess the Relative Bioavailability of BMS-986435 Tablet Formulations in Healthy Adult Participants

The purpose of this study is to assess the relative bioavailability of BMS-986435 tablet formulations in healthy adult male and female participants.

Inclusion Criteria:

• Body weight of ≥ 45 kg and a body mass index (BMI) between 18 and 32 kg/m^2, inclusive.
• Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) and clinical laboratory assessments.
• Have documented left ventricular ejection fraction (LVEF) ≥ 60% and absence of significant cardiac abnormality.

Exclusion Criteria:

• Any acute or chronic medical illness.
• History of heart disease.
• Prior exposure to BMS-986435.
• Other protocol-defined Inclusion/Exclusion criteria apply.